PT1336409E - Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas. - Google Patents

Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas. Download PDF

Info

Publication number
PT1336409E
PT1336409E PT03007342T PT03007342T PT1336409E PT 1336409 E PT1336409 E PT 1336409E PT 03007342 T PT03007342 T PT 03007342T PT 03007342 T PT03007342 T PT 03007342T PT 1336409 E PT1336409 E PT 1336409E
Authority
PT
Portugal
Prior art keywords
omega
snx
binding
mviia
quot
Prior art date
Application number
PT03007342T
Other languages
English (en)
Portuguese (pt)
Inventor
Gary Arthur Amstutz
Peter Isadore Adriaenssens
Ramasharma Kristipati
Mark Raymond Pettus
Stephen Scott Bowersox
Theresa Gadbois
Robert R Luther
Kishochandra Gohil
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of PT1336409E publication Critical patent/PT1336409E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
PT03007342T 1995-06-27 1996-06-26 Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas. PT1336409E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
PT1336409E true PT1336409E (pt) 2007-06-29

Family

ID=27052304

Family Applications (2)

Application Number Title Priority Date Filing Date
PT03007342T PT1336409E (pt) 1995-06-27 1996-06-26 Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas.
PT96923511T PT835126E (pt) 1995-06-27 1996-06-26 Composicoes e formulacoes para a producao de analgesia e para a inibicao de patologias dolorosas neuropaticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT96923511T PT835126E (pt) 1995-06-27 1996-06-26 Composicoes e formulacoes para a producao de analgesia e para a inibicao de patologias dolorosas neuropaticas

Country Status (13)

Country Link
EP (2) EP0835126B1 (enExample)
JP (1) JP2838073B2 (enExample)
AT (2) ATE359086T1 (enExample)
AU (1) AU695166B2 (enExample)
CA (1) CA2224795C (enExample)
DE (3) DE69627153T2 (enExample)
DK (2) DK0835126T3 (enExample)
ES (2) ES2283671T3 (enExample)
FR (1) FR05C0027I2 (enExample)
LU (1) LU91181I2 (enExample)
NL (1) NL300201I2 (enExample)
PT (2) PT1336409E (enExample)
WO (1) WO1997001351A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
WO1999042480A1 (en) * 1998-02-20 1999-08-26 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
WO2004050688A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
DK1572725T3 (da) 2002-12-02 2012-06-18 Xenome Ltd Chi-conotoksinpeptider med en N-terminal pyroglutaminsyre
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004007105T2 (de) 2003-01-28 2008-02-28 Microbia Inc., Cambridge Zusammensetzung zur behandlung von gastrointestinalen störungen
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
WO2008054171A1 (en) * 2006-11-04 2008-05-08 Anygen Co., Ltd. Omega conotoxins
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
EP2300044A4 (en) * 2008-05-06 2012-04-18 Relevare Aust Pty Ltd METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010065751A2 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
CA2151741C (en) * 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
DE122005000043I1 (de) 2006-06-29
CA2224795A1 (en) 1997-01-16
EP1336409A1 (en) 2003-08-20
HK1058146A1 (en) 2004-05-07
DE122005000043I2 (de) 2006-08-03
JP2838073B2 (ja) 1998-12-16
ATE235914T1 (de) 2003-04-15
DE69637021D1 (de) 2007-05-24
JPH09104634A (ja) 1997-04-22
FR05C0027I1 (enExample) 2005-08-12
LU91181I2 (fr) 2005-09-06
PT835126E (pt) 2003-07-31
DK0835126T3 (da) 2003-07-14
AU6400296A (en) 1997-01-30
ATE359086T1 (de) 2007-05-15
DE69627153T2 (de) 2003-12-04
NL300201I1 (nl) 2005-09-01
ES2283671T3 (es) 2007-11-01
EP0835126B1 (en) 2003-04-02
DE69627153D1 (de) 2003-05-08
EP1336409B1 (en) 2007-04-11
CA2224795C (en) 2001-04-03
ES2194998T3 (es) 2003-12-01
DE69637021T2 (de) 2008-01-10
FR05C0027I2 (enExample) 2006-12-29
NL300201I2 (nl) 2006-02-01
AU695166B2 (en) 1998-08-06
WO1997001351A1 (en) 1997-01-16
EP0835126A1 (en) 1998-04-15
DK1336409T3 (da) 2007-08-13

Similar Documents

Publication Publication Date Title
PT1336409E (pt) Composições e formulações para a produção de analgesia e para a inibição da progressão de patologias dolorosas neuropáticas.
US5795864A (en) Stable omega conopetide formulations
Taylor Agents acting at the neuromuscular junction and autonomic ganglia
Sandkühler et al. Spinal somatostatin superfusion in vivo affects activity of cat nociceptive dorsal horn neurons: comparison with spinal morphine
US20040138204A1 (en) Compositions and methods for pain reduction
Yu et al. Dexmedetomidine enhances ropivacaine-induced sciatic nerve injury in diabetic rats
Li et al. Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA [1, 2] and GeXIVA [1, 4] in rats of neuropathic pain
Westlund et al. A rat knockout model implicates TRPC4 in visceral pain sensation
BR112020020346A2 (pt) Neurotoxinas para uso na inibição de cgrp
Boettger et al. Spinally applied ketamine or morphine attenuate peripheral inflammation and hyperalgesia in acute and chronic phases of experimental arthritis
WO2018068670A1 (zh) 神经兴奋性损伤相关多肽在预防、缓解或治疗疼痛的用途
BR112021007083A2 (pt) tratamento de doença neurológica com zilucoplan
Valle et al. Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice
Wiktelius et al. Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1–7
JP2011522012A (ja) ペプチドトキシンＡＰＥＴｘ２の鎮痛作用
Canduz et al. Epidural lornoxicam administration–innocent
Sheets et al. Inhibition of Nav1. 7 and Nav1. 4 sodium channels by trifluoperazine involves the local anesthetic receptor
Liu et al. Pacemaking activity in the peripheral nervous system: Physiology and roles of hyperpolarization activated and cyclic nucleotide-gated channels in neuropathic pain
Nyman et al. The amino-terminal heptapeptide of the algesic substance P provides analgesic effect in relieving chronic neuropathic pain
Zhang et al. Novel endomorphin analogues CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favourable side effect profile at the spinal level
Goldhill et al. Mechanism of tachykinin NK3 receptor-mediated colonic ion transport in the guinea pig
US20080112954A1 (en) Method for treating chronic pain
ES2808667T3 (es) Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta
HK1058146B (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
Daniel Peripheral analgesic activity